AI VIVO is pioneering organism-level drug discovery. Our platform — Organome and OrganoDesign — is a unique generative AI that fuses generative biology and generative chemistry to identify novel targets and design drugs at the organ level, moving beyond the target-binding paradigm where most drugs still fail on unexpected organism-level surprises in the clinic. By embedding that complexity at the design phase, we are advancing an internal pipeline across fibrosis, metabolic disease, immunology, and aging, with multiple validated programmes, and offering Fast Track partnerships for disease modelling, target discovery, and organ-level drug design.
Peyman Gifani, Chief Executive Officer & Founder, AI VIVO
